Serdexmethylphenidate/dexmethylphenidate effects on sleep in children with attention-deficit/hyperactivity disorder

被引:0
作者
Mattingly, Greg W. [1 ]
Childress, Ann C. [2 ]
Cutler, Andrew J. [3 ,4 ]
Estrada, Jose [5 ]
Corliss, Meg [5 ]
机构
[1] Washington Univ, Sch Med, Midwest Res Grp, St Louis, MO 63130 USA
[2] Ctr Psychiat & Behav Med, Las Vegas, NV USA
[3] SUNY Upstate Med Univ, Syracuse, NY USA
[4] Neurosci Educ Inst, Lakewood Ranch, FL USA
[5] Corium LLC, Boston, MA USA
来源
FRONTIERS IN PSYCHIATRY | 2023年 / 14卷
关键词
ADHD; Azstarys; Children's Sleep Habits Questionnaire; dexmethylphenidate; SDX; d-MPH; serdexmethylphenidate; sleep; METHYLPHENIDATE; ADHD;
D O I
10.3389/fpsyt.2023.1193455
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
IntroductionSleep-related problems are common in children with attention-deficit/hyperactivity disorder (ADHD). Sleep disorders are also side effects of all stimulant ADHD medications. Serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) is a once-daily treatment approved for patients age 6 years and older with ADHD. In this analysis, sleep behavior was assessed during SDX/d-MPH treatment in children with ADHD. MethodsIn a 12-month, dose-optimized, open-label safety study in 6- to 12-year-old participants (NCT03460652), a secondary endpoint was assessment of sleep behavior based on the Children's Sleep Habits Questionnaire (CSHQ) consisting of 8 sleep domains (bedtime resistance, sleep onset delay, sleep duration, sleep anxiety, night wakings, parasomnias, sleep-disordered breathing, and daytime sleepiness). This post hoc analysis examined the individual sleep domains in the 12-month safety study. ResultsOf 282 participants enrolled, 238 were included in the sleep analysis. At baseline, mean (SD) CSHQ total sleep disturbance score was 53.4 (5.9). After 1 month of treatment, the mean (SD) CSHQ total score significantly decreased to 50.5 (5.4); least-squares mean change from baseline was -2.9 (95% CI: -3.5 to -2.4; p < 0.0001) and remained decreased up to 12 months. Mean sleep-score improvements from baseline to 12 months were statistically significant (p < 0.0001) for 5 of 8 sleep domains, including bedtime resistance, sleep anxiety, night wakings, parasomnias, and daytime sleepiness. Parasomnias and daytime sleepiness sleep domains showed the greatest mean improvement from baseline to 12 months. Sleep onset delay and sleep duration scores increased from baseline to 12 months. No statistically significant worsening occurred from baseline in sleep duration and sleep-disordered breathing domains; however, worsening of sleep onset delay was statistically significant. ConclusionIn this analysis of children taking SDX/d-MPH for ADHD, sleep problems did not worsen based on the mean CSHQ total sleep disturbance score. Statistically significant improvements in most CSHQ sleep domains were observed after 1 month and lasted for up to 12 months of treatment.
引用
收藏
页数:7
相关论文
共 15 条
  • [1] Effects of Methylphenidate on Sleep Functioning in Children with Attention-Deficit/Hyperactivity Disorder
    Becker, Stephen P.
    Froehlich, Tanya E.
    Epstein, Jeffery N.
    [J]. JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS, 2016, 37 (05) : 395 - 404
  • [2] Briars Leslie, 2016, J Pediatr Pharmacol Ther, V21, P192, DOI 10.5863/1551-6776-21.3.192
  • [3] Safety and Tolerability of Serdexmethylphenidate/Dexmethylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder: A 12-Month, Open-Label Safety Study
    Childress, Ann C. C.
    Marraffino, Andrea
    Cutler, Andrew J. J.
    Oh, Charles
    Brams, Matthew N. N.
    [J]. JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2023, 33 (02) : 51 - 58
  • [4] Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis
    Cortese, Samuele
    Adamo, Nicoletta
    Del Giovane, Cinzia
    Mohr-Jensen, Christina
    Hayes, Adrian J.
    Carucci, Sara
    Atkinson, Lauren Z.
    Tessari, Luca
    Banaschewski, Tobias
    Coghill, David
    Hollis, Chris
    Simonoff, Emily
    Zuddas, Alessandro
    Barbui, Corrado
    Purgato, Marianna
    Steinhausen, Hans-Christoph
    Shokraneh, Farhad
    Xia, Jun
    Cipriani, Andrea
    [J]. LANCET PSYCHIATRY, 2018, 5 (09): : 727 - 738
  • [5] The sleep of children with attention deficit hyperactivity disorder on and off methylphenidate: a matched case-control study
    Galland, Barbara C.
    Tripp, E. Gail
    Taylor, Barry J.
    [J]. JOURNAL OF SLEEP RESEARCH, 2010, 19 (02) : 366 - 373
  • [6] Associations of sleep disturbance with ADHD: implications for treatment
    Hvolby, Allan
    [J]. ADHD-ATTENTION DEFICIT AND HYPERACTIVITY DISORDERS, 2015, 7 (01) : 1 - 18
  • [7] Stimulant Medications and Sleep for Youth With ADHD: A Meta-analysis
    Kidwell, Katherine M.
    Van Dyk, Tori R.
    Lundahl, Alyssa
    Nelson, Timothy D.
    [J]. PEDIATRICS, 2015, 136 (06) : 1144 - 1153
  • [8] The effect of OROS methylphenidate on the sleep of children with attention-deficit/hyperactivity disorder
    Kim, Hyo-Won
    Yoon, In-Young
    Cho, Soo-Churl
    Kim, Boong-Nyun
    Chung, Seockhoon
    Lee, Hyewon
    Kim, Chi-Won
    Park, Sung-Kun
    Yoo, Hee Jeong
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2010, 25 (02) : 107 - 115
  • [9] A Randomized, Controlled Laboratory Classroom Study of Serdexmethylphenidate and d-Methylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder
    Kollins, Scott H.
    Braeckman, Rene
    Guenther, Sven
    Barrett, Andrew C.
    Mickle, Travis C.
    Oh, Charles
    Marraffino, Andrea
    Cutler, Andrew J.
    Brams, Matthew N.
    [J]. JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2021, 31 (09) : 597 - 609
  • [10] Owens JA, 2000, SLEEP, V23, P1043